Clopidogrel in Critically Ill Patients
Open Access
- 15 September 2017
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 103 (2) , 217-223
Abstract
Only limited data are available regarding the treatment of critically ill patients with clopidogrel. This trial investigated the effects and the drug concentrations of the cytochrome P450 (CYP450) activated prodrug clopidogrel (n = 43) and the half‐life of the similarly metabolized pantoprazole (n = 16) in critically ill patients. ADP‐induced aggregometry in whole blood classified 74% (95% confidence intervals 59–87%) of critically ill patients as poor responders (n = 43), and 65% (49–79%) responded poorly according to the vasodilator‐stimulated phosphoprotein phosphorylation (VASP‐P) assay. Although the plasma levels of clopidogrel active metabolite normally exceed the inactive prodrug ∼30‐fold, the parent drug levels even exceeded those of the metabolite 2‐fold in critically ill patients. The half‐life of pantoprazole was several‐fold longer in these patients compared with reference populations. The inverse ratio of prodrug/active metabolite indicates insufficient metabolization of clopidogrel, which is independently confirmed by the ∼5‐fold increase in half‐life of pantoprazole. Thus, high‐risk patients may benefit from treatment with alternative platelet inhibitors.Keywords
Funding Information
- Austrian Science Funds (SFB54P04)
This publication has 33 references indexed in Scilit:
- Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet FunctionJACC, 2013
- Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS‐PCI studyJournal of Thrombosis and Haemostasis, 2012
- CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersEuropean Journal of Clinical Pharmacology, 2012
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 TrialEuropean Heart Journal, 2011
- Quantification of pantoprazole in human plasma using LC-MS/MS for pharmacokinetics and bioequivalence studyEuropean Journal of Drug Metabolism and Pharmacokinetics, 2010
- Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine DiphosphateJACC, 2010
- A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarctionCatheterization and Cardiovascular Interventions, 2009
- Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery diseaseEuropean Heart Journal, 2009
- Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsisCritical Care Medicine, 2004